Claims:

1. Crystalline Form Type A of Formula IX as its HCl salt



(IX),

characterized by an X-ray powder diffraction pattern comprising peaks at 12.0, 21.8, 25.9, 26.7, and 27.9 degrees 2θ (± 0.2 degrees 2θ).

2. The crystalline Form Type A of Formula IX as its HCl salt according to claim 1, further characterized by an X-ray powder diffraction pattern comprising peaks at 7.0, 10.4, 13.0, and 13.9 degrees 2θ (± 0.2 degrees 2θ).

3. The crystalline Form Type A of Formula IX as its HCl salt according to claim 1 or 2, further characterized by an X-ray powder diffraction pattern comprising peaks at 15.6 and 17.0 degrees 2θ (± 0.2 degrees 2θ).

4. Crystalline Form Type A of Formula IX as its HCl salt according to claim 1, characterized by an X-ray powder diffraction pattern substantially in accordance with **FIG. 31**.

5. Crystalline Form Type A of Formula IX as its HCl salt of any one of claims 1 to 4, which is substantially free of other Formula IX crystalline or amorphous forms.

6. Crystalline Form Type A of Formula IX as its HCl salt according to any one of claims 1 to 4, further characterized by a weight loss ranging from 0.7% to 1.9% upon heating to around 150 °C, as measured by thermal gravimetric analysis.

7. Crystalline Form Type A of Formula IX as its HCl salt according to claim 6, wherein the weight loss is about 1.3%.

8. Crystalline Form Type A of Formula IX as its HCl salt according to any one of claims 1 to 7, characterized by water uptake of about 1.6 % at 25 °C / 80 % relative

humidity (RH) after undergoing a dynamic vapor sorption cycle which includes pre-equilibration at 0 % RH.

9. Crystalline Form Type A of Formula IX as its HCl salt according to any one of claims 1 to 8, characterized by gains of less than 2.5% weight after undergoing a dynamic vapor sorption cycle from 0 % relative humidity (RH) to 90% RH.

10. Crystalline Form Type A of Formula IX as its HCl salt according to any one of claims 1 to 9, having a dynamic vapor sorption profile substantially as shown in **FIG. 37**.

11. Crystalline Form Type A of Formula IX as its HCl salt according to any one of claims 1 to 7, further characterized by a differential scanning calorimetry thermogram comprising endothermic peaks at around 211-214 and 237-239 °C.

12. Crystalline Form Type A of Formula IX as its HCl salt according to claim 11, wherein, said differential scanning calorimetry thermogram comprises endothermic peaks around 11.7, 212.6, and 237.3°C.

13. Crystalline Form Type A of Formula IX as its HCl salt in accordance with any one of claims 1 to 12, for use in therapy.

14. Use of crystalline Form Type A of Formula IX as its HCl salt in accordance with any one of claims 1 to 12, in the preparation of a medicament for the treatment of a transthyretin (TTR) amyloid disease.

15. Use of Crystalline Form Type A of Formula IX as its HCl salt in accordance with any one of claims 1 to 12, in the preparation of a medicament for the treatment of TTR amyloid cardiomyopathy.

16. Use of Crystalline Form Type A of Formula IX as its HCl salt in accordance with any one of claims 1 to 12 in the preparation of a medicament for the treatment of TTR amyloid polyneuropathy.